title: What is the appropriate management for a patient with CIN1 on colposcopy?
abstract: Of the different strategies available for managing cervical intraepithelial neoplasia grade 1 (CIN1), testing for high-risk subtypes of the human papillomavirus (hr-HPV) DNA at 12 months has the highest sensitivity for predicting the development of CIN2 or CIN3 and leads to the lowest rate of referral to repeat colposcopy. If the hr-HPV DNA test result is negative at 12 months, then the patient may return to routine cytology screening. If the hr-HPV DNA test result is positive, the patient should undergo repeat colposcopy.
authors.affiliation: St. Joseph's Hospital Family Practice Residency, Fayetteville, NY, USA.
authors.forename: Erin
authors.initials: E
authors.lastname: Avrich
authors.forename: Sandra
authors.initials: S
authors.lastname: Sulik
authors.forename: Joan
authors.initials: J
authors.lastname: Nashelsky
mesh_terms: D003127:Colposcopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009367:Neoplasm Staging / Q000379:methods; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis*